Meeting
2016 ASCO Annual Meeting
Efficacy of nivolumab and ipilimumab (Nivo + Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP).
Authors
Alexander Noor Shoushtari
Memorial Sloan Kettering Cancer Center, New York, NY
Alexander Noor Shoushtari , Pedram Navid-Azarbaijani , Claire Frances Friedman , Katherine Panageas , Michael Andrew Postow , Margaret K. Callahan , Parisa Momtaz , Shonnette C. Campbell , Yelena Shames , Nana A. Prempeh-Keteku , Kasiemobi Nwaedozie , Jedd D. Wolchok , Paul B. Chapman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02186249
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9554)
DOI
10.1200/JCO.2016.34.15_suppl.9554
Abstract #
9554
Poster Bd #
159
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).
First Author: Charlee Nardin
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.
First Author: Jianbo Wang
Poster
2022 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitor (ICI) rechallenge in advanced melanoma patients responders to a first course of ICI: A multicenter, national, retrospective study of the French group of skin cancers (GCC).
First Author: Charlee Nardin
Poster
2022 ASCO Annual Meeting
The effect of the microbiome on immune checkpoint inhibitor toxicity in patients with melanoma.
First Author: Nyelia Williams